Organon & Co. (OGN)

Market Cap	1.90B -50.7%
Revenue (ttm)	6.22B -2.9%
Net Income	187.00M -78.4%
EPS	0.72 -78.4%
Shares Out	260.32M
PE Ratio	10.13
Forward PE	2.10
Dividend	$0.08 (1.11%)
Ex-Dividend Date	Feb 23, 2026

Volume	3,740,188
Open	7.21
Previous Close	7.23
Day's Range	7.08 - 7.34
52-Week Range	6.18 - 16.08
Beta	0.55
Analysts	Hold
Price Target	11.75 (+61.18%)
Earnings Date	Feb 12, 2026

About OGN

Organon & Co. develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally. The company's women’s health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1923
• Employees: 10,000
• Stock Exchange: NYSE
• Ticker Symbol: OGN
• Website: https://www.organon.com

Financial Performance

In 2025, Organon & Co.'s revenue was $6.22 billion, a decrease of -2.92% compared to the previous year's $6.40 billion. Earnings were $187.00 million, a decrease of -78.36%.

Analyst Summary

According to 4 analysts, the average rating for OGN stock is "Hold." The 12-month stock price target is $11.75, which is an increase of 61.18% from the latest price.

Price Target

$11.75

(61.18% upside)

Analyst Consensus: Hold